GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Total Operating Expense

Apollon Formularies (AQSE:APOL) Total Operating Expense : £0.45 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Total Operating Expense?

Apollon Formularies's Total Operating Expense for the six months ended in Jun. 2023 was £0.45 Mil. Apollon Formularies's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 was £0.45 Mil.


Apollon Formularies Total Operating Expense Historical Data

The historical data trend for Apollon Formularies's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Total Operating Expense Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.43 0.46 0.06 0.96

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.34 0.62 0.54 0.45

Apollon Formularies Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012